These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23929242)

  • 1. [Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].
    Speth F; Wellinghausen N; Haas JP
    Z Rheumatol; 2013 Nov; 72(9):896-909. PubMed ID: 23929242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Screening investigations during intensified immunosuppression in children and adolescents. Part 1].
    Speth F; Wellinghausen N; Haas JP
    Z Rheumatol; 2013 Oct; 72(8):814-21. PubMed ID: 23929241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vaccination recommendations of the Commission for Pharmacotherapy of the German Society of Rheumatology].
    Warnatz K; Goldacker S; Gause AM;
    Z Rheumatol; 2013 Sep; 72(7):687-9. PubMed ID: 23929238
    [No Abstract]   [Full Text] [Related]  

  • 4. [Vaccination in adult patients with chronic inflammatory rheumatic diseases].
    Goldacker S; Gause AM; Warnatz K;
    Z Rheumatol; 2013 Sep; 72(7):690-4, 696-700, 702-4. PubMed ID: 23929239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic strategies: Ways to remission].
    Krüger K; Edelmann E
    Z Rheumatol; 2015 Jun; 74(5):386-7. PubMed ID: 26085071
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].
    Diel R; Hauer B; Loddenkemper R; Manger B; Krüger K
    Pneumologie; 2009 Jun; 63(6):329-34. PubMed ID: 19517358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intra-articular injection of cortisone].
    Hammer M; Schwarz T; Ganser G
    Z Rheumatol; 2015 Nov; 74(9):774-9. PubMed ID: 26511366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia.
    Wong PKK; Bagga H; Barrett C; Hanrahan P; Johnson D; Katrib A; Leder K; Marabani M; Pentony P; Riordan J; White R; Young L
    Intern Med J; 2017 May; 47(5):491-500. PubMed ID: 28101910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TPMT testing in rheumatology: any better than routine monitoring?
    Payne K; Newman W; Fargher E; Tricker K; Bruce IN; Ollier WE
    Rheumatology (Oxford); 2007 May; 46(5):727-9. PubMed ID: 17255139
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases.
    Zingarelli S; Airò P; Frassi M; Bazzani C; Scarsi M; Puoti M
    Reumatismo; 2008; 60(1):22-7. PubMed ID: 18432322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Injection treatment with hyaluronic acid].
    Jerosch J
    Z Rheumatol; 2015 Nov; 74(9):764-73. PubMed ID: 26431953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.
    Stine JG; Khokhar OS; Charalambopoulos J; Shanmugam VK; Lewis JH
    Arthritis Care Res (Hoboken); 2010 May; 62(5):704-11. PubMed ID: 20461789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Communicating the risk of side effects to rheumatic patients.
    Martin RW
    Rheum Dis Clin North Am; 2012 Nov; 38(4):653-62. PubMed ID: 23137575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Personalized medicine in the choice of conventional immunosuppressants and disease modifying antirheumatic drugs].
    Fiehn C; Keyßer G; Lorenz HM
    Z Rheumatol; 2013 Feb; 72(1):27-40. PubMed ID: 23247868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
    Woodworth TG; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day R; Lipani J; Brooks P
    J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologist.
    Pincus T; Braun J; Kavanaugh A; Smolen JS
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S1-3. PubMed ID: 24129127
    [No Abstract]   [Full Text] [Related]  

  • 17. Pentostatin (Nipent) and high-dose cyclophosphamide for the treatment of refractory autoimmune disorders.
    Goodman M
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):67-71. PubMed ID: 10877056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients.
    Schwaneck EC; Krone M; Kreissl-Kemmer S; Weißbrich B; Weiss J; Tony HP; Gadeholt O; Schmalzing M; Geier A
    Clin Rheumatol; 2018 Nov; 37(11):2963-2970. PubMed ID: 30238380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheumatology science and practice in India.
    Misra DP; Sharma A; Agarwal V
    Rheumatol Int; 2018 Sep; 38(9):1587-1600. PubMed ID: 30022301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria.
    Niehues T; Horneff G; Michels H; Höck MS; Schuchmann L; ;
    Rheumatol Int; 2005 Apr; 25(3):169-78. PubMed ID: 15688190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.